Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)
Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.